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Introduction {#sec005}
============

Thyroid cancer in children and adolescents is one of the most common rare tumors, as defined by TREP in Brazil \[[@pone.0232416.ref001]\]. According to a recent cancer incidence in five continents (CI5C) monograph, Brazil has the highest incidence rates within South and Central America \[[@pone.0232416.ref002]\]. An increased incidence of thyroid cancer in adults and childhood has been reported in several countries \[[@pone.0232416.ref003], [@pone.0232416.ref004], [@pone.0232416.ref005]\]. However, the magnitude of the effects of overdiagnosis and increased environmental risk factors on this higher incidence is not well known. In children, thyroid nodule screening is less likely to occur and recent data from North American Association of Central Cancer Registries showed that large and late-stage thyroid carcinomas are increasing over time \[[@pone.0232416.ref006]\].

A recent analysis of rare tumors in children and adolescents (0--19 years old) in Brazil showed different incidence rates of thyroid carcinomas in Brazilian geographic regions varying from 1.87 per million in the North region to 6.48 per million in the Southeast region. Incidence rates increase with age and were found to be the highest among adolescents (15--19 years old) \[[@pone.0232416.ref001]\], Incidence rates in Latin American in adolescents and young adults (AYAs) are the most common cancer in females was thyroid cancer, with rates ranging from 0.9 to 10.0/100,000 \[[@pone.0232416.ref007]\]. It is well described that the increase is attributable to an increase in incidence of the histologic subtype papillary thyroid cancer. Clinicopathological characteristics of young patients with thyroid carcinomas seem to differ from those of adults. The lymph node metastasis rate is significantly higher, but distant metastases are lower in AYAs \[[@pone.0232416.ref008]\]. Sociodemographic disparities are described as prognostic factors affecting survival among the AYA group, with a worse prognosis in socioeconomically deprived groups \[[@pone.0232416.ref009]\].

Thyroid cancer is a common second malignancy in children with cancer \[[@pone.0232416.ref010]\]. The cause of the increasing incidence remains to be established, but enhanced screening diagnostic and others factors should be investigated. Few risk factors have been described. Exposure to ionizing radiation is the most established risk factor. Irradiation in childhood or young adulthood increases the risk of nodules and papillary thyroid cancer \[[@pone.0232416.ref011]\]. The prevalence of incidental thyroid abnormalities detected by ultrasound in **Korean** adults is about 13--67% \[[@pone.0232416.ref012]\]. In children, few reports have studied the prevalence of ultrasound-detected findings in the thyroid, with the exception of screening programs conducted around Chernobyl \[[@pone.0232416.ref013]\]. A survey including thyroid ultrasound examinations for children aged ≤18 years was conducted in Japanese children unaffected by radioactive material from the Fukushima Nuclear Power Plant accident, and thyroid nodules were identified in 1.6% of participants; 99% were classified as 'no further examination required' \[[@pone.0232416.ref014], [@pone.0232416.ref015]\]. Neck ultrasound done for other reasons detected incidental thyroid abnormalities in 18% of children, and the majority were cystic lesions. No malignancy was found in this group of patients \[[@pone.0232416.ref016]\]. In addition, increased iodine intake, obesity, and higher birth weight have also been described as potential risk factors \[[@pone.0232416.ref017], [@pone.0232416.ref018], [@pone.0232416.ref019]\].

The objective of this study was to analyze trends of incidence rates in thyroid carcinomas among children and AYAs (0--39 years) in Brazil, and provide suggestions for further investigations into descriptive and etiological epidemiology.

Materials and methods {#sec006}
=====================

Incidence data were obtained from 11 population-based cancer registries (PBCRs) encompassing the five geographic regions of Brazil: North (Belém and Palmas), Northeast (Aracaju, João Pessoa and Recife), Midwest (Goiânia), Southeast (Barretos, Belo Horizonte, Jahu and São Paulo), and South (Curitiba). [Table 1](#pone.0232416.t001){ref-type="table"} shows the population coverage of children (0--14 years old) and AYAs (15--39 years old) for each city, providing PBCR data in five geographic regions during the period of coverage. ([Table 1](#pone.0232416.t001){ref-type="table"})

10.1371/journal.pone.0232416.t001

###### Population of children and AYAs in five Brazilian geographic regions of the 11 PBCR, 2000--2013.

![](pone.0232416.t001){#pone.0232416.t001g}

  Local                  Age-group    
  ---------------------- ------------ ------------
  **North region**                    
  Belém                  7,032,422    12,088,341
  Palmas                 839,998      1,432,022
  **Northeast region**                
  Aracaju                1,855,000    3,388,063
  João Pessoa            2,375,388    4,285,109
  Recife                 5,042,777    9,268,313
  **Midwest region**                  
  Goiânia                4,031,550    8,023,995
  **Southeast region**                
  Belo Horizonte         7,325,583    14,613,982
  Barretos               1,335,602    2,354,375
  Jahu                   387,548      733,590
  São Paulo              35,610,705   66,924,283
  **South region**                    
  Curitiba               5,535,231    10,821,232

Source: MP/Fundação Instituto Brasileiro de Geografia e Estatística--IBGE

The International Classification of Disease for Oncology, second and third editions \[[@pone.0232416.ref020], [@pone.0232416.ref021]\] was used according to histological group papillary, follicular, other carcinomas, and not otherwise specified (NOS) carcinomas. Other carcinomas included all other carcinoma subtypes found at the 11 PBCRs ([Table 2](#pone.0232416.t002){ref-type="table"}).

10.1371/journal.pone.0232416.t002

###### Thyroid carcinomas studied, with ICD-O2 and ICD-O3 topography and morphology codes.

![](pone.0232416.t002){#pone.0232416.t002g}

  Classification                                           Morphology codes                                                                                                         Topography code
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ -----------------
  Papillary                                                8050, 8052, 8130, 8260, 8340--8344, 8450, 8452                                                                           C73
  Follicular                                               8290, 8330--8332, 8335                                                                                                   
  Others carcinomas[\*](#t002fn001){ref-type="table-fn"}   8020, 8021, 8030, 8070, 8074, 8140, 8190, 8200, 8230, 8246, 8262, 8310, 8337, 8345, 8350, 8380, 8430, 8510, 8511, 8550   
  Carcinomas, NOS                                          8000--8010                                                                                                               

\* Others carcinomas includes all others carcinomas subtypes found in 11 PBCR

Abbreviation: ICD-02; ICD-03: International Classification of Disease for Oncology, 2^nd^/ 3^rd^ Edition; NOS: not other specified

[Table 3](#pone.0232416.t003){ref-type="table"} presents data quality indicators. NOS morphology codes (8000--8010) were higher than 10% in two PBCRs. Only four PBCRs had different than zero, as ascertained by death certificate only. The rate of microscopically verified cases was over 85% in 10 PBCRs, and only 1 had a rate below 75%.

10.1371/journal.pone.0232416.t003

###### Data quality indicators from 11 Brazilian PBCR in cases aged \<39 years diagnosed during the period 2000--2013.

![](pone.0232416.t003){#pone.0232416.t003g}

  PBCR             Total number of cases   NOS%    DCO%    MV%
  ---------------- ----------------------- ------- ------- -------
  North                                                    
  Belém            156                     8.3     0.6     97.4
  Palmas           22                      0.0     0.0     90.9
  Northeast        ** **                   ** **   ** **   ** **
  Aracaju          483                     0.6     0.0     99.8
  João Pessoa      120                     12.5    0.0     97.5
  Recife           220                     7.3     0.5     96.4
  Midwest          ** **                   ** **   ** **   ** **
  Goiânia          591                     1.2     0.0     73.4
  Southeast                                                
  Barretos         111                     7.2     0.0     100,0
  Belo Horizonte   377                     0.0     0.3     99.5
  Jahu             36                      0.0     0.0     100,0
  São Paulo        8513                    14.5    0.0     88.7
  **South**        ** **                   ** **   ** **   ** **
  Curitiba         452                     1.5     0.2     98.0

Abbreviations: PBCR: population-based cancer registry; NOS: Not otherwise specified; DCO: Death certificate only; MV: Microscopically verification

To estimate crude incidence rates, we divided the numbers of incident cases during the period of diagnosis by the corresponding person-years lived within the general population during the same period for each PBCR. Age-adjusted incidence rates (AAIRs) were estimated by the direct method, using the world population estimated for gender and age groups, and were analyzed according to age group \[[@pone.0232416.ref022]\]. Age-specific incidence rates (ASRs) per million were analyzed according to age at diagnosis, with the age range stratified into seven groups: 0--9, 10--14, 15--19, 20--24, 25--29, 30--34, and 35--39 years of age. Incidence trends were estimated with annual average percent change (AAPC) and corresponding confidence intervals (CIs) with Joinpoint software (version 4.6.0.0). P values less than 0.05 were considered statistically significant \[[@pone.0232416.ref023]\].

All data used for this analysis were public access data and ethical approval was not required.

Results {#sec007}
=======

Between 2000 and 2013, we identified a Brazilian pool from 11 PBCRs of 11.081 children and AYAs (0--39 years) with thyroid carcinoma (AAIR of 41.64 cases per million). [Table 4](#pone.0232416.t004){ref-type="table"} presents the number of cases and ASRs per million incidence rates according to gender by geographic region. ASR increased with age, and females had a higher ASR in all age groups. Geographic variation was observed and the Midwest and Southeast regions had the highest ASRs in all age groups, although among children 10--14 years of age, the South region had a higher ASR. The lowest ASR in all age groups was found in the North region. ASR in all age groups and PBCR can be seen in Supporting additional table ([S1 Table](#pone.0232416.s001){ref-type="supplementary-material"}). There are an increase with age and female has a higher ASR in all age groups.

10.1371/journal.pone.0232416.t004

###### Numbers of cases and incidence rates of thyroid carcinomas in five Brazilian regions by gender in cases aged \<40 years and diagnosed during the period 2000--2013.

![](pone.0232416.t004){#pone.0232416.t004g}

  Gender           Local   Age-group                                                               
  ---------------- ------- ----------- ------ -------- -------- -------- -------- -------- ------- -------
  Total            North   6           0.76   0.67     172      12.72    12.55    178      8.32    7.13
  Northeast        10      1.08        0.94   813      47.99    46.00    823      31.39    25.46   
  Midwest          \*\*    1.24        1.02   586      73.03    70.14    591      49.02    38.63   
  Southeast        103     2.24        1.99   8 934    102.65   94.92    9 037    67.96    52.56   
  South            12      2.17        1.77   440      40.66    38.03    452      27.63    21.50   
  Brazilian pool   136     1.87        1.64   10 945   80.28    75.14    11 081   53.02    41.64   
  Females          North   \*\*        1.28   1.10     94       13.25    20.21    108      9.82    11.50
  Northeast        7       1.53        1.36   693      77.61    73.21    700      51.81    40.45   
  Midwest          \*\*    1.51        1.23   487      116.46   110.98   490      79.36    60.95   
  Southeast        72      3.08        2.77   7 507    163.46   150.20   7 579    109.39   82.98   
  South            8       2.94        2.93   377      68.11    63.12    385      46.63    35.43   
  Brazilian pool   95      2.60        2.29   9 210    128.51   119.36   9 305    85.98    65.99   
  Males            North   \*\*        0.25   0.24     26       4.05     4.04     27       2.60    2.31
  Northeast        \*\*    0.64        0.52   120      14.98    14.71    123      9.68     8.24    
  Midwest          \*\*    0.98        0.81   99       25.77    25.15    101      17.17    14.05   
  Southeast        31      1.37        1.20   1 427    34.71    32.38    1 458    22.89    18.16   
  South            \*\*    1.42        1.17   63       11.92    11.34    67       8.27     6.70    
  Brazilian pool   41      1.14        0.98   1 735    26.83    25.41    1 776    17.62    14.27   

\* less than 5 cases

Abbreviations: N: number of cases; ASR: age-specific rate; AAIR: Age-adjusted incidence rate; PBCR population-based cancer registries

[Fig 1](#pone.0232416.g001){ref-type="fig"} shows the ratio distribution by histologic subtypes according to age group. The most common histologic subtype in all 11 PBCRs was papillary, accounting for more than 70%. The non-specified group was the least common among adolescents (15--19 years old), and the group classified as other carcinomas was most common in the 10 to 14-year-old age group.

![Percentage distribution by histologic subtypes according to age group.](pone.0232416.g001){#pone.0232416.g001}

In [Table 5](#pone.0232416.t005){ref-type="table"}, morphologic subtypes according to gender shows that females and AYAs (15--39 years old) and papillary subtype had the highest CRs and AAIRs.

10.1371/journal.pone.0232416.t005

###### Numbers of cases and crude and age-adjusted incidence rate of thyroid carcinoma according to age group, gender and histologic subtypes.

![](pone.0232416.t005){#pone.0232416.t005g}

  Age-group           Histologic type   Gender                                                                                                        
  ------------------- ----------------- ------------ ------------ ----------- ----------- ----------- ------------ ----------- ----------- ---------- ------
  **0--14**           Papillary         77           2.11         1.86        26          0.72        0.62         103         1.4         1.3        2.93
  Follicular          \*\*              0.08         0.07         \*\*        0.08        0.07        6            0.1         0.1         1.00       
  Others carcinomas   6                 0.16         0.15         \*\*        0.11        0.09        10           0.1         0.1         1.45       
  Carcinomas, NOS     9                 0.25         0.21         8           0.22        0.20        17           0.2         0.2         1.14       
  **Total**           **95**            **2.60**     **2.29**     **41**      **1.14**    **0.98**    **136**      **1.87**    **1.64**    **2.28**   
  **15--39**          Papillary         7 292        101.75       94.54       1 389       21.48       20.33        8 681       63.67       59.61      4.74
  Follicular          620               8.65         8.10         82          1.27        1.21        702          5.15        4.85        6.81       
  Others carcinomas   206               2.87         2.68         71          1.10        1.08        277          2.03        1.93        2.61       
  Carcinomas, NOS     1 092             15.24        14.04        193         2.98        2.80        1285         9.42        8.75        5.11       
  **Total**           **9 210**         **128.51**   **119.36**   **1 735**   **26.83**   **25.41**   **10 945**   **80.28**   **75.14**   **4.79**   
  **0--39**           Papillary         7 369        68.09        52.29       1 415       14.04       11.34        8 784       42.03       33.00      4.85
  Follicular          623               5.76         4.44         85          0.84        0.69        708          3.39        2.67        6.86       
  Others carcinomas   212               1.96         1.52         75          0.74        0.63        287          1.37        1.10        2.65       
  Carcinomas, NOS     1 101             10.17        7.74         201         1.99        1.61        1 302        6.23        4.86        5.11       
  **Total**           **9 305**         **85.98**    **65.99**    **1 776**   **17.62**   **14.27**   **11 081**   **53.02**   **41.64**   **4.88**   

\* less than 5 cases

Abbreviations: N: number of cases; CR: crude rate; AAIR: age-adjusted incidence rate

The female:male ratio was 2.28 among children 0--14 years old and 4.79 for AYAs (15--39 years old). Rates increased for both age groups, children and AYAs. Among children, less than 15 years old, an increase in papillary histologic subtype was only seen in the São Paulo PBCR. Among AYAs (15--39 years), there was a significant increase in different Brazilian geographic regions. Belo Horizonte, which is located in the Midwest region, had the highest rate of increase (AAPC 13.8 \[7.4; 20.6\] ([Table 6](#pone.0232416.t006){ref-type="table"}).

10.1371/journal.pone.0232416.t006

###### Trend of thyroid carcinomas incidence by gender, age group and Brazilian region.

Age-adjusted rate and AAPC, period 2000--2013.

![](pone.0232416.t006){#pone.0232416.t006g}

  Variable           0--14                                     15--39                                                                             
  ------------------ ----------------------------------------- -------- ------------------------------------------------------- -------- -------- -------------------------------------------------------
  Total              136                                       1.64     18.8[\*](#t006fn001){ref-type="table-fn"} (8.1; 30.6)   10 945   75.14    7.9[\*](#t006fn001){ref-type="table-fn"} (5.6; 10.3)
  Gender                                                                                                                                          
  Female             95                                        2.29     23.2[\*](#t006fn001){ref-type="table-fn"} (4.4; 45.3)   9 210    119.36   7.8[\*](#t006fn001){ref-type="table-fn"} (5.5; 10.2)
  Male               41                                        0.98     \-                                                      1 735    25.41    8.6[\*](#t006fn001){ref-type="table-fn"} (5.2; 12.1)
  Histologic group                                                                                                                                
  Papillary          103                                       1.25     17.6[\*](#t006fn001){ref-type="table-fn"} (8.3; 27.7)   8 681    63.67    10.8[\*](#t006fn001){ref-type="table-fn"} (8.6; 13.1)
  Follicular         6                                         0.07     \-                                                      702      5.15     -0.6 (-8.0; 7.4)
  Brazillian PBCR                                                                                                                                 
  North Region                                                                                                                                    
  Belém              [\*\*](#t006fn002){ref-type="table-fn"}   0.63     \-                                                      151      12.28    4.2[\*](#t006fn001){ref-type="table-fn"} (0.4; 8.1)
  Palmas             [\*\*](#t006fn002){ref-type="table-fn"}   1.06     \-                                                      21       14.82    \-
  Northeast Region                                                                                                                                
  Aracaju            [\*\*](#t006fn002){ref-type="table-fn"}   2.20     \-                                                      478      136.39   8.6[\*](#t006fn001){ref-type="table-fn"} (4.5; 12.9)
  João Pessoa        [\*\*](#t006fn002){ref-type="table-fn"}   1.02     \-                                                      117      26.15    \-
  Recife             [\*\*](#t006fn002){ref-type="table-fn"}   0.44     \-                                                      218      22.87    4.3 (-3.1; 12.4)
  Midwest Region                                                                                                                                  
  Goiânia            [\*\*](#t006fn002){ref-type="table-fn"}   1.02     \-                                                      586      70.14    3.2[\*](#t006fn001){ref-type="table-fn"} (0.5; 5.9)
  Southeast Region                                                                                                                                
  Barretos           [\*\*](#t006fn002){ref-type="table-fn"}   1.33     \-                                                      109      43.86    4.5 (-0.7; 9.9)
  Belo Horizonte     [\*\*](#t006fn002){ref-type="table-fn"}   0.33     \-                                                      374      24.27    13.8[\*](#t006fn001){ref-type="table-fn"} (7.4; 20.6)
  Jahu               0                                         0.00     \-                                                      36       45.99    \-
  São Paulo          98                                        2.37     15.9[\*](#t006fn001){ref-type="table-fn"} (8.1; 30.6)   8 415    111.83   8.7[\*](#t006fn001){ref-type="table-fn"} (5.7; 11.9)
  South Region                                                                                                                                    
  Curitiba           12                                        1.77     \-                                                      440      38.03    1.0 (-1.9; 3.9)

\* less than 5 cases

\*\**p*-value \< 0.05

N: number of cases; AAIR: Age-adjusted incidence rate; AAPC: Annual average percent change; PBCR: population-based cancer registries

Overall, the incidence rates significantly increased in children (0--14) and AYAs (15--39), from 0.19 in 2000 to 2.80 in 2013 and from 47.11 in 2000 to 115.30 in 2013, respectively ([Fig 2](#pone.0232416.g002){ref-type="fig"}). In the two age groups, the incidence of papillary subtype increased from 0.35 in 2001 to 2.19 in 2013 for children and from 31.48 in 2000 to 100.39 in 2013 for AYAs. For the follicular subtype, the incidence was stable during the study period for AYAs only ([Fig 2](#pone.0232416.g002){ref-type="fig"}).

![Incidence trends of thyroid carcinoma (A) and by histologic subtype, papillary (B) and follicular (C) in children and AYAs.](pone.0232416.g002){#pone.0232416.g002}

Discussion {#sec008}
==========

To the best of our knowledge, this is the first descriptive analysis of Brazilian PBCRs regarding thyroid carcinomas in children and AYAs. During the period of 2000--2013, the rates of thyroid carcinoma significantly increased among children and AYAs in Brazil. The incidence rate for children 0--9 years old was 0.51 per million, increasing with age and predominating in females. Children10--14 years old had about a 9-fold greater incidence than younger children 0--9 years old. AYAs had a 4-fold greater incidence than children (0--14 years). There was a female preponderance at all ages. Incidence rates were 4.4, 17.5, 39.2, and 76.7 per million for the 10--14, 15--19, 20--24, and 25--29 year age groups, respectively, similar to the United States Surveillance, Epidemiology, and End Results (US SEER) data \[[@pone.0232416.ref024]\] during 1984--2010.

The increasing incidence rate (1973--2002) has been reported worldwide for the total population and does not appear to be geographically dependent \[[@pone.0232416.ref025], [@pone.0232416.ref026]\]. The reasons why the incidence of thyroid carcinoma has been increasing are still a subject of debate. Improved diagnosis does not completely explain the incidence trends; rather the increasing incidence is most likely due to a mixture of factors including increased exposure to risk factors. In our series, the overall incidence rates in children (0--14 years old) and AYAs (15--39 years old) significantly increased from 0.2 in 2000 to 2.8 in 2013, and from 47.1 in 2000 to 115.3 in 2013, respectively. The US SEER data did not change in children between 0 and 9 years old, but increasing trends were seen in children from 10 to 14 years old and AYAs, similar to adults \[[@pone.0232416.ref024]\]. Recently, a significantly increased rate was seen among children and adolescents aged 10 to 19 years \[[@pone.0232416.ref006]\]. All tumor sizes were noted to increase rates, which cannot be explained by screening only, but may also be affected by environmental and others factors. These data are in accordance with data from adults showing that the observed incidence increased for all tumor sizes, suggesting that early diagnosis is not the only explanation \[[@pone.0232416.ref005]\]. Unfortunately, we did not have access to stage and size of tumor at diagnosis in this population set.

Our study showed differences among geographic regions. During the period of 1997--2008, data comparing the incidence rates from São Paulo located in the Southeast region of Brazil and from the US SEER showed that Sao Paulo had the highest increase in incidence for all age groups. A previous study suggested that not only a better diagnosis but also differences in iodine nutrition may affect the incidence of this disease \[[@pone.0232416.ref018]\]. In this report, among children 0--14 years old, we observed a significantly increased incidence rate, possibly attributed to the fact that the Sao Paulo PBCR had the largest number of cases in this age group. Among AYAs of both genders, there was a significantly increased incidence of the papillary subtype. The highest increase in incidence was observed in Aracaju in the Northeast region and in Belo Horizonte and Sao Paulo located in the Southeast region of Brazil.

Few reports has described in children the prevalence of ultrasound-detected findings in the thyroid and routine screening ultrasound in children is not recommended unless they are high risk \[[@pone.0232416.ref013], [@pone.0232416.ref014], [@pone.0232416.ref015], [@pone.0232416.ref027]\]. Overall, the annual number of imaging diagnostic procedures has rapidly increased in Brazil. Overall ultrasound (any site) increased from 13 million to 309 million between 2000 and 2013. (<http://www2.datasus.gov.br/>).

A strong association between radiation exposure and risk of thyroid cancer is well documented. After the Chernobyl nuclear accident and more recently after the Fukushima Daiichi Nuclear Power Plant, a significant increase in pediatric thyroid carcinoma has been observed in children living in contaminated areas \[[@pone.0232416.ref013], [@pone.0232416.ref015]\]. In children treated with irradiation for cancer, thyroid carcinoma is one of the most common second malignancies \[[@pone.0232416.ref011]\]. The use of X-ray and computed tomography (CT) as medical and dental diagnostic sources has increased during the last two decades, and are associated with an increased thyroid cancer risk \[[@pone.0232416.ref028]\]. Available data has shown increased of dental x-ray of 1% during the period 2008 to 2019 among children, adolescents and young adults (<http://www2.datasus.gov.br/>). The use of CT is widespread in pediatric settings and delivers greater radiation doses than conventional X-rays \[[@pone.0232416.ref029]\]. Dose of radiation and number of CT scans, which can lead to the development of cancer, depends on multiple factors such as the specific type of CT, the patient's age, and gender.

High iodine in diet has been associated with thyroiditis, hypothyroidism, hyperthyroidism, increased risk of papillary carcinoma, and decreased risk of follicular carcinoma \[[@pone.0232416.ref030], [@pone.0232416.ref031]\]. In this study, there was a smaller number of follicular carcinomas and no trends were observed in children and AYAs. Brazil has changed from iodine deficiency to excessive iodine nutritional intake (<http://189.28.128.100/dab/docs/portaldab/documentos/pnaisal_relatorio_final.pdf>).

The role of iodine in the pathogenesis of thyroid cancer is controversial, and the difference has been documented according to tumor histology. Iodine deficiency is associated with follicular carcinoma, whereas excess iodine increases the risk of papillary type of thyroid cancer \[[@pone.0232416.ref030]\].

In a recent cohort study from Denmark, birth weight was associated with risk of thyroid cancer and significantly with follicular carcinoma, but these data need to be confirmed \[[@pone.0232416.ref017]\]. In a Brazilian record linkage analysis regarding birth weight, minor differences were observed among the mean birth weight for tumor types and controls. For the miscellaneous group including the carcinoma group, a risk of 1.37 (CI: 0.71--2.66) was observed for each additional 1000 g of birth weight \[[@pone.0232416.ref032]\].

Several studies have shown the relationship between overweight and different cancer types including thyroid cancer \[[@pone.0232416.ref019], [@pone.0232416.ref033]\]; however, this has not been shown in children. Childhood obesity has been increasing worldwide. This increasing prevalence has emerged as an important public health problem and has possibly led to the emergence of multiple serious obesity-related comorbidities. The prevalence of obesity among children and adolescents in Brazil has also significantly increased, from 5.4% to 8.5% in girls and boys and from 6.2% to 8.4% in the age group of 5--9 years during 2008--2018. Among adolescents girls, it increased from 3.4% to 7.3% during the same period (<http://sisaps.saude.gov.br/sisvan/relatoriopublico/estadonutricional>).

Clinical presentation and outcomes in pediatric patients is significantly different compared to adults \[[@pone.0232416.ref034], [@pone.0232416.ref035]\]. Distinct genetic alterations have been suggested. *RET*/PTC rearrangement is the most prevalent genetic alteration found in sporadic and radiation-induced pediatric thyroid papillary carcinomas \[[@pone.0232416.ref036]\]. In a recent series of 35 Brazilian pediatric patients with thyroid papillary carcinoma, it was confirmed that *RET*/ PTC rearrangement was the most prevalent mutation. The spectrum of mutations was similar to that described in radiation-exposed pediatric papillary carcinoma, suggesting that all thyroid carcinomas may be radiation-induced \[[@pone.0232416.ref036], [@pone.0232416.ref037]\]. Mutation in the *BRAF* gene is the most common abnormality in adult papillary thyroid carcinoma, but is very rare in children \[[@pone.0232416.ref038], [@pone.0232416.ref039]\].

As shown in a previous report, the incidence of thyroid carcinomas was higher for all ages in the Midwest, Southeast, and South regions of Brazil, with the highest percentages observed in white residents \[[@pone.0232416.ref001], [@pone.0232416.ref040]\]. Unfortunately, we do not have reliable data among the PBCRs regarding race/skin color. We observed an increasing incidence of thyroid carcinoma, both papillary and follicular, in children and AYAs in Brazil that can be attributed to several risk factors, such as overdiagnosis; however, others factors must be investigated. Excess iodine intake, obesity, radiation for diagnostic reasons, prevention, and environmental exposure should be investigated.

A major limitation of this study is that there is no information regards size and stage of tumors. Another major limitation is that risk factors as use of radiation, is unknown. We cannot generalize this data to entire Brazil. These 11 PBCR cover approximately 20% of the total Brazilian population.

In conclusion, it was not possible to identify the exact cause or causes of this notable rise in incidence, mainly for papillary carcinomas, in both populations. Increased diagnostic activity may play a role, but is not likely to be the only reason because incidence continues to rise rather than levelling off at some point in time. Future studies especially in Sao Paulo should attempt to retrieve tumor stage and size in order to determine the role of advances in diagnostic accuracy, and to evaluate the impact of iodine prophylaxis on papillary and follicular carcinoma incidence patterns.

Supporting information {#sec009}
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###### Numbers of cases and age-specific incidence rates of thyroid carcinomas in five Brazilian regions, 11 PBCR in cases aged \<40 years and diagnosed during the period 2000--2013.
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Reviewer \#1: Thank you for giving me the opportunity to review this paper about thyroid carcinoma in children, adolescents, and young adults in Brazil. The authors are to be congratulated for performing a clinically relevant study concerning real world data of 11 cancer registries in Brazil.

Introduction

The authors should put the informationof risk factors and genetic alterations (line 220-266) in the introduction section, as the introduction should provide information about thyroid cancer in adolescents and young adults to the reader. Otherwise, the paper is hard to follow and lacks of a logical flow. This would also help to shorten the dicussion section.

Materials and methods

Statement of ethical approval is not applicable

Joinpoint regression is a feasible and commonly used method for analyzing cancer trends.

Discussion

The authors should use the discussion section to clearly present their results concerning the different regions of Brazil. In its current form, the discussion section is too lengthy and the authors may divide the discussion into section headings.

There should be a section about gender differences.

Reviewer \#2: Authors should discuss the following in the revised manuscript:

To see whether the increase in incidence was due to overdiagnosis through screening, authors should have stratified the sample by stage at diagnosis.

If they found higher early stage at diagnosis, then the likelihood of the increase in incidence rate is due to screening becomes more likely.

If authors have no access to stage at diagnosis, they should refer readers to other studies that have investigated trends in stage at diagnosis during same time period. Then they could speculate according to comparisons.

Also, authors should speculate that the increase could be due to exposure to radiation at dental office (they can add references). They also should refer to other studies to at least shed lights on possible etiology. For instance, is the southern region more developed areas of the countries where access to dental services is higher than other region and that's why residents are more likely to get exposed to risk factors? The same thing apply to Iodine exposure.

I'd also suggest authors to include graphs about linear changers (AAPC) over time.

By looking at the location of the selected registries, most of them from are from southeast region which contains a very large population compare to the rest of the regions. It will be good discuss this point in the discussion too.

Finally, authors should add limitation section and enlist all that apply.

Reviewer \#3: PONE-D-19-34167: Thyroid carcinoma in children, adolescents, and young adults in Brazil: A report from 11 population-based cancer registries

Summary: The study by de Camargo et al. examined the incidence and trends of thyroid cancer among children (0-14 years) and young adults (15-39 years) in Brazil. The investigators analyzed data from 11 population-based cancer registries. They calculated age-adjusted incidence rates (AAIR), age specific incidence rates (ASIR), and changes in incidence trends between 2000-2013 using jointpoint regression analyses. The results show an AAIR of 42 cases per a million persons. The incidence rate was higher in females than males. Participants of age 15-39 years had higher incidence rate than those of age 0-14. The trend analysis also increasing incidence of thyroid cancer in Brazil between 2000 and 2013. Overall, this is an important study that addresses a knowledge gap of the patterns of thyroid cancer incidence in the Brazilian population. Below are suggestions for improvement.

1\. Why did the investigators express the incidence rate per one million persons? Typically, incidence rates are expressed per 100,000 population. The use of a million-population estimate will make it difficult to compare the incidence rate with that of other populations that have used the typical 100,000 population. The investigators should consider revising the estimated population rate to 100,000 instead of a million.

2\. Data from 11 population-based cancer registries were analyzed. Why were these registries chosen? What proportion of the Brazilian population do these registries represent? The concern here is generalizability of the findings to the broader Brazilian population.

3\. For the subgroup comparisons, e.g., comparison between males and females, please provide p-values showing significant differences between groups. In other words, is the estimate for females significantly different from that of males? We know that the estimated values are different but are the estimates significantly different from each other?

4\. "AYAs had a 40-fold greater incidence than children (0--14 years)." What values were used to calculate the 40-fold difference?

5\. In the abstract, please indicate the age ranges used to classify participants into children vs. older adults for easy comprehension.

6\. Abstract, please correct "11.081" as 11,081.

7\. The ICD-02 and 03 codes used to identify the thyroid cancer cases, are these the standard codes? Can you cite a reference or two indicating the appropriateness of these codes?

8\. Death certificates are not reliable for classifying cancer cases. Please remove the 4 cases determined by death certificates alone from the analyses.

9\. Some of the Tables don't fit into the manuscript space (e.g., Table 4). Please reformat the table, possibly using smaller font size.

10\. A link to a pdf document was provided in the Discussion but the document appears to be in Portuguese. Is there an English version of the document?

Reviewer \#4: This kind of manuscript, which carries demographic data of Brazilian population without any molecular identification, therefor this report will useful for national journal.

This kind of study need to more case and case control for analysis as age, sex and disease match.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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Reviewer \#3: Yes: Samuel O. Antwi
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Reviewer \#1: Thank you for giving me the opportunity to review this paper about thyroid carcinoma in children, adolescents, and young adults in Brazil. The authors are to be congratulated for performing a clinically relevant study concerning real world data of 11 cancer registries in Brazil.

Introduction

The authors should put the information of risk factors and genetic alterations (line 220-266) in the introduction section, as the introduction should provide information about thyroid cancer in adolescents and young adults to the reader. Otherwise, the paper is hard to follow and lacks of a logical flow. This would also help to shorten the dicussion section.

R: Thank you for the comment, we add risk factors in the Introduction and shorten the discussion.

Added to introduction (lines 75-85): "The prevalence of incidental thyroid abnormalities detected by ultrasound in Korean adults is about 13--67% \[12\]. In children, few reports have studied the prevalence of ultrasound-detected findings in the thyroid, with the exception of screening programs conducted around Chernobyl \[13\]. A survey including thyroid ultrasound examinations for children aged ≤18 years was conducted in Japanese children unaffected by radioactive material from the Fukushima Nuclear Power Plant accident, and thyroid nodules were identified in 1.6% of participants; 99% were classified as 'no further examination required' \[14, 15\]. Neck ultrasound done for other reasons detected incidental thyroid abnormalities in 18% of children, and the majority were cystic lesions. No malignancy was found in this group of patients \[16\]."

We deleted from discussion:

(line 241): "High iodine intake, obesity, and high birth weight are risk factors for thyroid cancer."

(lines 259-265): "In a recent evaluation of urinary iodine concentrations in schoolchildren from all Brazilian regions, the highest concentration was seen in the Northeast region (298.80µg/L). In the Amazon state located in the North region, the median urinary iodine concentration was low (197.60 µg/L). One-fifth of the children had adequate intake (20.4%) presenting urinary iodine concentrations between 100 and199 µg/L, while 25.2% had more than adequate intake and 44.6% had excessive iodine intake (≥ 300 µg/L)"

(lines 283-285): "In several countries, the prevalence of obesity has almost doubled: in Israel, it increased from 5.8% in 1975 to 11.9% in 2016, Andorra from 6.2% to 12.8%, and Malta from 7.4% to 13.4% \[32\]."

Materials and methods

Statement of ethical approval is not applicable

R: Included in Material and Methods: "All data used for this analysis were public access data and thus that ethical approval this study was not required."

Discussion

The authors should use the discussion section to clearly present their results concerning the different regions of Brazil. In its current form, the discussion section is too lengthy and the authors may divide the discussion into section headings.

There should be a section about gender differences.

R: We shorten the discussion as describe above. It was included gender differences.

Reviewer \#2: Authors should discuss the following in the revised manuscript:

To see whether the increase in incidence was due to overdiagnosis through screening, authors should have stratified the sample by stage at diagnosis.

If they found higher early stage at diagnosis, then the likelihood of the increase in incidence rate is due to screening becomes more likely.

If authors have no access to stage at diagnosis, they should refer readers to other studies that have investigated trends in stage at diagnosis during same time period. Then they could speculate according to comparisons.

R: We agree with the reviewer and recognize the relevance of the information about the stage and size tumor, but unfortunately, we do not have data, and it was included as a major limitation.

Also, authors should speculate that the increase could be due to exposure to radiation at dental office (they can add references). They also should refer to other studies to at least shed lights on possible etiology. For instance, is the southern region more developed areas of the countries where access to dental services is higher than other region and that's why residents are more likely to get exposed to risk factors? The same thing apply to Iodine exposure.

R: Unfortunately, we do not have precise data of risk factors and the best we could provide we included in the discussion: "Available data has shown increased of dental x-ray of 1% during the period 2008 to 2019 among children, adolescents and young adults (<http://www2.datasus.gov.br/>)."

I'd also suggest authors to include graphs about linear changers (AAPC) over time.

R. Figure three includes AAPC over time (lines 194-195).

By looking at the location of the selected registries, most of them from are from southeast region which contains a very large population compare to the rest of the regions. It will be good discuss this point in the discussion too.

R: We agree with the reviewer and included in the Discussion: "A major limitation of this study is that there is no information regards size and stage of tumors. Another major limitation is that risk factors as use of radiation, is unknown. These 11 PBCR cover approximately 20% of the total Brazilian population so we cannot generalize this data to entire Brazil."

Finally, authors should add limitation section and enlist all that apply.

R: See above.

Reviewer \#3: PONE-D-19-34167: Thyroid carcinoma in children, adolescents, and young adults in Brazil: A report from 11 population-based cancer registries

Summary: The study by de Camargo et al. examined the incidence and trends of thyroid cancer among children (0-14 years) and young adults (15-39 years) in Brazil. The investigators analyzed data from 11 population-based cancer registries. They calculated age-adjusted incidence rates (AAIR), age specific incidence rates (ASIR), and changes in incidence trends between 2000-2013 using jointpoint regression analyses. The results show an AAIR of 42 cases per a million persons. The incidence rate was higher in females than males. Participants of age 15-39 years had higher incidence rate than those of age 0-14. The trend analysis also increasing incidence of thyroid cancer in Brazil between 2000 and 2013. Overall, this is an important study that addresses a knowledge gap of the patterns of thyroid cancer incidence in the Brazilian population. Below are suggestions for improvement.

1\. Why did the investigators express the incidence rate per one million persons? Typically, incidence rates are expressed per 100,000 population. The use of a million-population estimate will make it difficult to compare the incidence rate with that of other populations that have used the typical 100,000 population. The investigators should consider revising the estimated population rate to 100,000 instead of a million.

R: In children, adolescents and young adults the incidence rate are more usually express per million persons in all paper because of rarity.

2\. Data from 11 population-based cancer registries were analyzed. Why were these registries chosen? What proportion of the Brazilian population do these registries represent? The concern here is generalizability of the findings to the broader Brazilian population.

R: Among the eleven PBCR eight cancer registries data were included in the Vol. X or XI of CI5C, the main publication of the WHO on cancer incidence, the other registries follow the same rules of the IARC for an exhaustive and of good quality registration \[Câncer no Brasil: dados dos registros de base populacional, vol. 4, INCA 2010. Available from: <https://www.inca.gov.br/publicacoes/livros/cancer-no-brasil-dados-dos-registros-de-base-populacional;> Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017) Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: <http://ci5.iarc.fr>\].

These 11 PBCRs cover approximately 20% of the total Brazilian population.

These was included in the limitations.

3\. For the subgroup comparisons, e.g., comparison between males and females, we included female:male ratio in table 4.

4\. "AYAs had a 40-fold greater incidence than children (0--14 years)." What values were used to calculate the 40-fold difference?

R: The values were in table 4 -- Crude incidence rate among children 0-14 (1.87) and curde incidence rate among AYA (80.28)

5\. In the abstract, please indicate the age ranges used to classify participants into children vs. older adults for easy comprehension.

R: It was included.

6\. Abstract, please correct "11.081" as 11,081.

R: It was corrected.

7\. The ICD-02 and 03 codes used to identify the thyroid cancer cases, are these the standard codes? Can you cite a reference or two indicating the appropriateness of these codes?

R: Yes the ICD-02 and ICD-03 are the International code of oncology disease. We included the reference.

8\. Death certificates are not reliable for classifying cancer cases. Please remove the 4 cases determined by death certificates alone from the analyses.

R: About the DCO, rules from International Agency for Research on Cancer (IARC) recommends to included them.

9\. Some of the Tables don't fit into the manuscript space (e.g., Table 4). Please reformat the table, possibly using smaller font size.

R: Thanks for notice we corrected all tables.

10\. A link to a pdf document was provided in the Discussion but the document appears to be in Portuguese. Is there an English version of the document?\]

R: No, unfortunately the document is only in Portuguese.

Reviewer \#4: This kind of manuscript, which carries demographic data of Brazilian population without any molecular identification, therefor this report will useful for national journal.

This kind of study need to more case and case control for analysis as age, sex and disease match.

R: Unfortunately there are few papers that includes molecular identification on incidence rates.

10.1371/journal.pone.0232416.r003
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Please check the manuscript for spelling mistakes, eg table 2 \"others carcinomas\" instead of \"other\".

Reviewer \#2: I would like to thank the authors for chosing PLOS ONE for publishing their results. I think they gave resonable justifications for all asked questions.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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